Evaluation of the Chinese herbal medicine Jinlida in type 2 diabetes patients based on stratification: Results of subgroup analysis from a 12-week trial

Journal of Diabetes

Volumn 10, Issue 2, 2018, Pages 112-120

  Tian, Jiaxing ^a,b   Lian, Fengmei ^a   Yang, Libo ^c   Tong, Xiaolin ^a  

^a INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^b BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^c HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

glycated hemoglobin; insulin resistance; Jinlida; stratification; type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE; HEMOGLOBIN A1C; HERBACEOUS AGENT; INSULIN; JINLIDA; METFORMIN; PLACEBO; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; AGE; ARTICLE; BODY MASS; CELL FUNCTION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIABETIC PATIENT; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SCREENING; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SEX; TREATMENT DURATION; ANALYSIS; BLOOD; CLINICAL TRIAL; FOLLOW UP; GLUCOSE INTOLERANCE; MIDDLE AGED; PROGNOSIS;

BIOMARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUGS, CHINESE HERBAL; FEMALE; FOLLOW-UP STUDIES; GLUCOSE INTOLERANCE; GLYCATED HEMOGLOBIN A; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 85020217163     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/1753-0407.12559     Document Type: Article

References (20)

1. Xu Y, Wang L, He J et al. Prevalence and control of diabetes in Chinese adults. JAMA. 2013; 310: 948–959.
2. Dagenais GR, Gerstein HC, Zhang X et al. Variations in diabetes prevalence in low-, middle-, and high-income countries: Results from the Prospective Urban and Rural Epidemiological Study. Diabetes Care. 2016; 39: 780–787.
3. Palmer AK, Tchkonia T, LeBrasseur NK, Chini EN, Xu M, Kirkland JL. Cellular senescence in type 2 diabetes: A therapeutic opportunity. Diabetes. 2015; 64: 2289–2298.
4. Potter KJ, Westwell-Roper CY, Klimek-Abercrombie AM, Warnock GL, Verchere CB. Death and dysfunction of transplanted β-cells: Lessons learned from type 2 diabetes? Diabetes. 2014; 63: 12–19.
5. Chiasson JL, Rabasa-Lhoret R. Prevention of type 2 diabetes: Insulin resistance and beta-cell function. Diabetes. 2004; 53 (Suppl.): S34–8.
6. Kahn SE, Zraika S, Utzschneider KM, Hull RL. The beta cell lesion in type 2 diabetes: There has to be a primary functional abnormality. Diabetologia. 2009; 52: 1003–1012.
7. Zhang L, Feng Y, List J, Kasichayanula S, Pfister M. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: Effects on glycaemic control and body weight. Diabetes Obes Metab. 2010; 12: 510–516.
8. Ishiguro H, Kodama S, Horikawa C et al. In search of the ideal resistance training program to improve glycemic control and its indication for patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Sports Med. 2016; 46: 67–77.
9. Tong X, Wu S, Lian F et al. The safety and effectiveness of TM81, a Chinese herbal medicine, in the treatment of type 2 diabetes: A randomized double-blind placebo-controlled trial. Diabetes Obes Metab. 2013; 15: 448–454.
10. Zhang Y, Li X, Zou D et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab. 2008; 93: 2559–2565.
11. Ji L, Tong X, Wang H et al. Efficacy and safety of traditional Chinese medicine for diabetes: A double-blind, randomised, controlled trial. PLoS One. 2013; 8: e56703.
12. Lian F, Li G, Chen X et al. Chinese herbal medicine Tianqi reduces progression from impaired glucose tolerance to diabetes: A double-blind, randomized, placebo-controlled, multicenter trial. J Clin Endocrinol Metab. 2014; 99: 648–655.
13. Lian F, Tian J, Chen X et al. The efficacy and safety of Chinese herbal medicine Jinlida as add-on medication in type 2 diabetes patients ineffectively managed by metformin monotherapy: A double-blind, randomized, placebo-controlled, multicenter trial. PLoS One. 2015; 10: e0130550.
14. Zhang Y, Wang W, Ning G. Study on the efficacy and safety of Jinlida in patients with inadequately controlled type-2 diabetes and dyslipidemia under life style intervention (ENJOY LIFE Study). J Diabetes. 2015; 7: 268–269.
15. Wang D, Tian M, Qi Y et al. Jinlida granule inhibits palmitic acid induced-intracellular lipid accumulation and enhances autophagy in NIT-1 pancreatic β cells through AMPK activation. J Ethnopharmacol. 2015; 161: 99–107.
16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28: 412–419.
17. Henry RR, Buse JB, Sesti G et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): A meta-analysis of the liraglutide development program. Endocr Pract. 2011; 17: 906–913.
18. Onishi Y, Oura T, Nishiyama H, Ohyama S, Takeuchi M, Iwamoto N. Subgroup analysis of Phase 3 studies of dulaglutide in Japanese patients with type 2 diabetes. Endocr J. 2016; 63: 263–273.
19. Raccah D, Miossec P, Esposito V, Niemoeller E, Cho M, Gerich J. Efficacy and safety of lixisenatide in elderly (≥65 years old) and very elderly (≥75 years old) patients with type 2 diabetes: An analysis from the GetGoal Phase III programme. Diabetes Metab Res Rev. 2015; 31: 204–211.
20. Pencek R, Blickensderfer A, Li Y, Brunell SC, Anderson PW. Exenatide twice daily: Analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index. Postgrad Med. 2012; 124: 21–32.